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Summary
Objectives: The prevalence of viral hepatitis varies worldwide. Although the prevalence of
hepatitis A virus (HAV) and hepatitis B virus (HBV) infection is generally low in Western countries,
pockets of higher prevalence may exist in areas with large immigrant populations. The aim of this
study was to obtain further information on the prevalence of viral hepatitis in a multi-ethnic area
in the Netherlands.
Methods: We conducted a community-based study in a multi-ethnic neighborhood in the city of
Rotterdam, the Netherlands, including both native Dutch and migrant participants, who were
tested for serological markers of hepatitis A, hepatitis B, and hepatitis C infection.
Results: Markers for hepatitis A infection were present in 68% of participants. The prevalence of
hepatitis B core antibodies (anti-HBc), a marker for previous or current infection, was 20% (58/
284). Prevalence of hepatitis A and B varied by age group and ethnicity. Two respondents (0.7%)
had chronic HBV infection. The prevalence of hepatitis C was 1.1% (3/271). High levels of isolated
anti-HBc were found.
Conclusions: We found a high prevalence of (previous) viral hepatitis infections. This confirms
previous observations in ethnic subgroups from a national general population study and illustrates
the high burden of viral hepatitis in areas with large immigrant populations.
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Introduction ity and acceptable precision of prevalence rates in sub-e10 I.K. Veldhuijzen et al.The prevalences of hepatitis A virus (HAV), hepatitis B virus
(HBV), and hepatitis C virus (HCV) infections vary worldwide.
While the geographical distributions of HAV and HBV differ
greatly between Western and non-Western countries, this
does not hold for HCV. Hepatitis A is transmitted fecal-orally,
hepatitis B through sexual contact, blood—blood contact,
and perinatally from mother to child, and hepatitis C mainly
parenterally. In the epidemiology of especially HAV and HBV
in low endemic regions, the import of cases from intermedi-
ate or high endemic regions plays an important role.
A population-based seroprevalence study in the Nether-
lands in 1995/1996, the so-called Pienter study, showed that
34% of the population had antibodies to HAV. The prevalence
increased with age and was higher in people of non-Dutch
ethnicity.1 In the Pienter study, a two-stage cluster sampling
technique was used to draw a nationwide sample. In each of
five geographic regions, with approximately equal numbers
of inhabitants, eight municipalities were sampled pro-
portionally to their size. Within each municipality, an age-
stratified sample of 380 individuals was drawn from the
population register.
Although the HBV prevalence is generally low in Western
countries, pockets of higher HBV prevalence exist in areas
with large immigrant populations. Therefore national pre-
valence figures can underestimate the burden of HBV infec-
tion. In the Netherlands, in the Pienter general population
study, the prevalence of antibodies to hepatitis B core
antigen (anti-HBc), a marker for past or current infection,
was 2.1%, and the prevalence of hepatitis B surface antigen
(HBsAg), which indicates chronic infection, was 0.2%.2 The
prevalence of chronic HBV in the Pienter study sample is
believed to be an underestimate due to under-representa-
tion of the non-Dutch population. An adjusted estimate,
based on the chronic HBV prevalence in the countries of
origin of first generation immigrants, defined as foreign
born, and their proportion in the Dutch population, resulted
in a new general population HBsAg prevalence estimate of
0.36%.3
The prevalence of hepatitis C in the general Dutch popu-
lation was estimated at 0.1% in the Pienter study. Most of the
HCV-infected individuals had no known risk factors.4
In this paper we present the results of a community-based
study in a multi-ethnic neighborhood in the city of Rotter-
dam, the Netherlands. Rotterdam has a large immigrant
population, with 26% of the population being first generation
immigrants and 19% second generation immigrants, in con-
trast to 10% and 9%, respectively, in the Netherlands overall
(Statistics Netherlands, data 2006). The aim of this study was
to obtain further information on the prevalence of viral
hepatitis in an area with a large immigrant population.
Patients and methods
Study population
A community-based study in a multi-ethnic neighborhood
of nearly 13 000 inhabitants in the south of Rotterdam was
carried out in 2004. We aimed at including a maximum
number of 800 participants in the study, a number based on
power calculations taking into consideration both feasibil-groups. People aged 18 to 65 years from the six main ethnic
groups in the neighborhood, namely Dutch, Moroccan,
Turkish, Surinamese, Antillean, and Cape Verdean, were
included in the sample. Ethnicity was based on the country
of birth of the person or of one of the parents. A random
sample of 1787 inhabitants of the neighborhood was drawn
from the municipal administration, stratified by ethnic
group. The number needed in each ethnic group was
calculated based on an expected overall response of
50%, with oversampling of those ethnic groups where a
lower response rate was anticipated. Foreign-born persons
are referred to as first generation migrants (FGM), persons
born in the Netherlands but with one of the parents born
abroad, as second generation migrants (SGM). Individuals
were invited by mail for a personal consultation at the
community center. Reminder letters were sent to groups
where response lagged. During the visit a blood sample was
taken, and based on an interview in the native language, a
questionnaire was filled in by the interviewer. The ques-
tionnaire included items on travel history, sexual behavior,
and risk factors such as intravenous drug use and other
parenteral exposures (e.g., medical procedures, tattoo) in
the Netherlands and abroad. Respondents provided written
informed consent and the study was approved by the
Medical Ethical Review Board of the Erasmus Medical Cen-
ter. The respondents received their test results by mail and
were offered free vaccination at the Municipal Public
Health Service (MPHS) if they were susceptible to HAV/
HBV.
Laboratory testing
All blood samples were tested for anti-HAV, anti-HCV, anti-
HBc, and HBsAg. Samples positive for anti-HBc and negative
for HBsAg were further tested for antibodies to hepatitis B
surface antigen (anti-HBs), and in the case of negative anti-
HBs also for antibodies to hepatitis B e-antigen (anti-HBe).
An anti-HBs level of less than 3 IU/l was considered nega-
tive. Anti-HAV, anti-HBc, HBsAg, and anti-HBe testing was
done with a microparticle enzyme immunoassay (MEIA,
Axsym, Abbott Laboratories). HBsAg-positive sera were
retested with a confirmation assay (Abbott Laboratories).
For anti-HBs testing, a quantitative MEIA was used, and for
anti-HCV testing an enzyme-linked immunosorbent assay
was used (ELISA, Axsym, Abbott Laboratories). Anti-HCV-
positive sera were confirmed by recombinant immunoblot
(Innogenetics).
Statistical analysis
Statistical analyses were performed using SPSS. To obtain
prevalence figures of previous infection with HAVand HBV for
the population in the neighborhood, weighted prevalences
were calculated using inverse probability weighting by sex
and ethnicity. In this procedure, weights are calculated for
each of the 12 sex/ethnicity groups by dividing the propor-
tion of a group in the neighborhood population by the pro-
portion of that group in the study population. Differences in
prevalence by sex and ethnicity were tested with Pearson’s
Chi-square test and by age group with Mantel—Haenszel Chi-
square tests for linear association.
Table 1 Prevalence of anti-HAV by sex, age group, and
ethnicity
n N % 95% CI p-Value
Overall 193 284 68% 62% 73%
Sex 0.536
Men 86 123 70% 61% 77%
Women 107 161 66% 59% 73%
Age group (years) <0.001
18—29 26 66 39% 29% 51%
30—44 83 119 70% 61% 77%
45—64 84 99 85% 76% 91%
Ethnicity <0.001a
Dutch 20 55 36% 25% 50%
Non-Dutch 173 229 76% 70% 81% <0.001b
FGM 163 205 80% 73% 84%
SGM 10 24 42% 24% 61%
Turkish 57 61 93% 84% 97%
Moroccan 49 50 98% 90% 100%
Surinamese 32 64 50% 38% 62%
Dutch Antillean 22 40 55% 40% 69%
Cape Verdean 13 14 93% 69% 99%
Age by ethnicity (years)
Dutch 0.003
18—29 0 9 0% 0% 30%
30—44 6 20 30% 15% 52%
45—64 14 26 54% 35% 71%
Non-Dutch <0.001
18—29 26 57 46% 33% 58%
30—44 77 99 78% 69% 85%
45—64 70 73 96% 89% 99%
FGM <0.001
18—29 18 38 47% 32% 63%
30—44 75 94 80% 72% 86%
45—64 70 73 96% 89% 99%
SGM 0.934
18—29 8 19 42% 23% 64%
30—44 2 5 40% 12% 77%
45—64 - -
CI, confidence interval, anti-HAV, anti-hepatitis A virus antibo-
dies; FGM, first generation migrants; SGM, second generation
migrants.
a p-Value of Dutch versus non-Dutch.
b p-Value of first generation migrants versus second generation
migrants.
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Of the 1787 people invited, 288 responded and came to the
community center. The overall response rate was 16%;
women participated more often than men (19% and 13%,
respectively). The response rate increased with age and was
10% in 18—29 year-olds, 17% in 30—44 year-olds, and 23% in
45—64 year-olds. Response also varied by ethnicity and was
9% in the Cape Verdean and Antillean groups, 17% in the
Surinamese and Moroccan groups, 23% in the Dutch group,
and 26% in the Turkish group. Fifty-five participants were
Dutch (19%) and 233 non-Dutch (81%), of whom 90% were first
generation migrants and 10% second generation migrants.Hepatitis A and hepatitis B test results were available for 284
participants, and hepatitis C results for 271 participants.
The overall prevalence of antibodies to hepatitis A was
68%, and corresponded with a prevalence of 50% (95% con-
fidence interval (CI) 44—55%) in the neighborhood when
weighted by sex and ethnicity. The prevalence increased
with age from 39% in the 18—29 years age group, to 85% in
the 45—64 years age group ( p < 0.001). Dutch respondents
had less evidence of previous HAV infection compared to
non-Dutch respondents: 36% and 76%, respectively
( p < 0.001). The difference in prevalence was especially
remarkable in the youngest age group, where none of the
Dutch respondents had antibodies to HAV compared to 46%
of the non-Dutch respondents. The anti-HAV prevalence
varied in the different non-Dutch ethnic groups; while
the overall prevalence was 50—55% in Surinamese and
Antillean respondents, it was over 90% in the Turkish,
Moroccan, and Cape Verdean respondents. Among non-
Dutch respondents, the prevalence in FGM was higher than
in SGM ( p < 0.001). The overall prevalence in SGM was
similar to that in Dutch respondents, but the oldest age
group was not represented among the SGM. The HAV pre-
valence in the 18—44 years age group was higher in SGM
compared to Dutch respondents, but this difference was not
statistically significant (Table 1).
The prevalence of anti-HBc, a marker for previous infec-
tion, was 20% (58/284) among respondents, and corre-
sponded with a prevalence of 16% (95% CI 12—21%) in the
neighborhood when weighted by sex and ethnicity. The pre-
valence increased with age from 8% in the 18—29 years age
group, to 27% in the 45—64 years age group ( p = 0.003).
Prevalence varied by ethnicity and was the lowest in Antil-
lean participants (3%) and highest in Cape Verdean partici-
pants (57%). The difference in prevalence between Dutch
participants and non-Dutch participants, 11% and 23%,
respectively, was not statistically significant. The anti-HBc
prevalence in FGM was higher than in SGM (25% and 4%,
respectively; p = 0.02). The prevalence of anti-HBc is
described in Table 2.
The overall prevalence of HBsAg, indicating chronic infec-
tion and infectivity, was 0.7% (2/284; 95% CI 0.1—2.3%) —
3.4% among anti-HBc-positives (2/58; 95% CI 0.6—10.9%). The
two patients with markers for chronic hepatitis B were both
FGM, a 41-year-old Turkish woman and a 53-year-old Antil-
lean man. Except ethnicity, no other risk factors could be
identified. The HBsAg prevalence in the total group of first
generation immigrants was 1.0% (95% CI 0.3—3.5%).
In 17% of anti-HBc-positives, no other markers of HBV
infection were found. If anti-HBc is present without HBsAg,
anti-HBs, or anti-HBe this is called isolated anti-HBc. The
prevalence of isolated anti-HBc varied by ethnicity and was
67% (4/6) among Dutch participants and 12% (6/52) among
non-Dutch participants ( p = 0.006).
Three respondents (1.1%, 95% CI 0.4—3.2%) were positive
for antibodies against HCV. They were a 57-year-old Surina-
mese man, a 20-year-old Moroccan man, and a 39-year-old
Antillean man. None of them reported intravenous drug use,
having had a tattoo, a piercing, contact with another per-
son’s blood, or a blood transfusion. The Surinamese man had
had surgery in the Netherlands; the other two men had been
subject to a medical procedure with a needle, the Moroccan
man abroad and the Antillean man in the Netherlands.
Table 2 Prevalence of anti-HBc by sex, age group, and
ethnicity
n N % 95% CI p-Value
Overall 58 284 20% 16% 25%
Sex 0.092
Men 31 122 25% 19% 34%
Women 27 162 17% 12% 23%
Age group (years) 0.003
18—29 5 66 8% 3% 17%
30—44 26 118 22% 16% 30%
45—64 27 100 27% 19% 36%
Ethnicity 0.057a
Dutch 6 55 11% 5% 22%
Non-Dutch 52 229 23% 18% 29% 0.022b
FGM 51 205 25% 19% 31%
SGM 1 24 4% 1% 20%
Turkish 23 60 38% 27% 51%
Moroccan 6 50 12% 6% 24%
Surinamese 14 65 22% 13% 33%
Dutch Antillean 1 40 3% 0% 13%
Cape Verdean 8 14 57% 33% 79%
Age by ethnicity (years)
Dutch 0.618
18—29 1 9 11% 2% 44%
30—44 3 20 15% 5% 36%
45—64 2 26 8% 2% 24%
Non-Dutch 0.001
18—29 4 57 7% 3% 17%
30—44 23 98 23% 16% 33%
45—64 25 74 34% 24% 45%
CI, confidence interval, anti-HBc, anti-hepatitis B core antigen;
FGM, first generationmigrants; SGM, second generationmigrants.
a p-Value of Dutch versus non-Dutch.
b p-Value of first generation migrants versus second generation
migrants.
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of birth. Five of them (29%; two Turkish and three Surina-
mese) reported visiting a travel clinic and receiving vaccina-
tions.
All respondents who were susceptible to hepatitis A and/
or hepatitis B were offered vaccination against hepatitis A
and/or hepatitis B free of charge. Sixty-three of 227 parti-
cipants (28%) took up the offer and visited the MPHS for
vaccination.
Discussion
We found high levels of previous infection with hepatitis A
and B in the multi-ethnic population of a neighborhood in
Rotterdam. The prevalences of chronic HBV (0.7%) and hepa-
titis C (1.1%) were higher than previously reported in the
national general population-based survey conducted in 1995/
1996 (the Pienter study), which reported prevalences of 0.2%
and 0.1%, respectively.
The response rate was lower than anticipated, despite the
community-based approach. Due to the low response rate,the total number of participants was small, which makes
comparisons between subgroups difficult. However, as we do
not assume that selective response by the outcome of viral
hepatitis testing has occurred, we consider the results of this
study valid. Our study is of interest for the city of Rotterdam,
but also for other cities with large immigrant populations.
In the Netherlands, vaccination against hepatitis A and B is
not included in the National Immunization Program (NIP).
However, since 2003, all children born to one or two parents
born in intermediate or high endemic countries have been
offered HBV immunization in the NIP. Furthermore, a vacci-
nation program for high-risk groups (commercial sex workers,
intravenous drug users, and men having sex with men) has
been in place since 2002.
The prevalences of HAV and HBV markers in the study
population were much higher than the general population
estimates in the Netherlands, because non-Dutch respon-
dents are over-represented in the targeted neighborhood
in Rotterdam. The HAV prevalence of more than 90% among
Turkish and Moroccan respondents (93% and 98%, respec-
tively) is comparable to that among Turkish and Moroccan
participants in the general population study (93% and 97%,
respectively).1 More than half of the participants of non-
Dutch ethnicity in the youngest age group were susceptible to
hepatitis A. The HBV prevalence found among Turkish and
Moroccan respondents (38% and 12%, respectively) is com-
parable to that among Turkish and Moroccan participants in
the general population study (39% and 19%, respectively).2
The anti-HBc prevalence increased with age, a finding also
observed in the general population study.2 Participants aged
18—29 years have low rates of previous HBV infection; over
90% of them are probably vulnerable to HBV infection. A small
part might be protected through vaccination, but we have no
information about this, as participants without markers for
previous or current HBV infection were not tested for the
presence of protective antibodies. Ninety-three percent of
the participants of non-Dutch ethnicity in the youngest age
group had nomarkers of previous HBV infection. The anti-HBc
prevalence was remarkably low in SGM, with only 1/24 SGM
found positive. This could suggest vaccination in this group,
which is however unlikely, as the pregnancy screening pro-
gram only started in 1989 and the participants in this study
were born before 1986. A possible explanation might be that
the risk of horizontal transmission in the Netherlands is lower
compared to that in the country of origin.
Five of the 17 SGM (29%; two Turkish and three Surina-
mese) who had visited their parent’s country of birth, went to
a travel clinic and were vaccinated. Although the type of
vaccination was not recorded, it most likely included hepa-
titis A vaccination. These results indicate a low vaccination
rate in SGM, especially Moroccan SGM, and many of them are
probably at risk of becoming infected with HAV while visiting
their home country. Active hepatitis A vaccination of Turkish
and Moroccan children has also been argued in a study among
children aged 5 to 16 years in Rotterdam.5 We would recom-
mend a more active approach in offering children in immi-
grant communities who did not receive HBV immunization as
part of the NIP, a combined hepatitis A and B immunization.
As could be expected, the 0.7% prevalence of chronic HBV
is also higher than the national estimate. The two HBsAg-
positives were first generation immigrants, and the preva-
lence of HBsAg in the total group of first generation immi-
Table 3 Hepatitis B prevalence (anti-HBc and HBsAg) in two observational studies and one theoretical estimation
Study Year Population Anti-HBc (%) HBsAg (%)
Pientera 1995/1996 General 2.1 0.2
Community-based study Rotterdamb 2004 Native Dutch 11 0
FGM 25 1.0
SGM 4 0
Overall 20 0.7
Marschall, theoretical estimatec 2007 General - 0.36
FGM - 3.77
Anti-HBc, anti-hepatitis B core antigen; HBsAg, hepatitis B surface antigen; FGM, first generation migrants; SGM, second generation
migrants.
a See reference 2.
b Present study.
c See reference 3.
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tically estimated HBsAg prevalence of 3.8% in first generation
immigrants in the Netherlands.3 Table 3 summarizes the anti-
HBc and HBsAg prevalences found in two observational field
studies in the Netherlands compared to the theoretical
estimates.
It is not uncommon to find high rates of isolated anti-HBc.
This serological profile can be the result of a previous infec-
tion with loss of measurable anti-HBs, of an ongoing low-
grade infection with undetectable HBsAg, or of a non-specific
reaction, i.e., a false-positive test result. Especially in popu-
lations with a low prevalence of HBVmarkers, the probability
of false-positive results increases.6 Studies in blood donors in
Brazil and Denmark reported false-positivity rates of 16% and
34%, respectively.7,8 The higher prevalence of isolated anti-
HBc found in Dutch participants (4/6) compared to non-Dutch
participants (6/52), and the absence of an increase in anti-
HBc prevalence with age, suggests false-positive results.
Therefore the prevalence of previous HBV infection of 11%
in Dutch participants is most likely an overestimation. How-
ever, our study does not provide enough evidence to conclude
which part of the cases of isolated anti-HBc were false-
positives, and therefore we have not excluded these cases
when calculating the anti-HBc prevalence. To get more
information on whether a person had a previous infection
with waning anti-HBs, one would have to give the person an
HBV vaccination and see if the anti-HBs response resembles a
primary or a secondary response. Isolated anti-HBc has been
shown to be associated with HCV, but none of the participants
with isolated anti-HBc found in this study had antibodies to
HCV.9
The prevalence of HCV infection found is higher than the
previous national estimate. Two of the three HCV-positive
participants were remarkably young at 20 and 39 years of
age. It is striking that the three HCV-infected respondents did
not report risk factors for HCV infection. This is contrary to
findings from a seroprevalence study in Amsterdam, where all
HCV-positive individuals were aged 43 or older, with known
HCV risk factors present in seven of nine.10
In conclusion, the results of this study show that within
low endemic countries, pockets with higher endemicity for
viral hepatitis do exist. This confirms previous observations in
ethnic subgroups from a national general population study
and illustrates the high burden of viral hepatitis in areas with
large immigrant populations.Acknowledgements
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